Lexicon Pharmaceuticals (LXRX) Stock Analysis

What Lexicon Pharmaceuticals does

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.

Key metrics

ETFs linked to LXRX

Broad-market and Healthcare sector ETFs an investor holding Lexicon Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LXRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals trades under the ticker LXRX on NASDAQ.

Which exchange is LXRX listed on?

LXRX is listed on NASDAQ.

What sector does Lexicon Pharmaceuticals operate in?

Lexicon Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze LXRX in a portfolio?

PortView shows LXRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.